March 27 (Reuters) - Affimed NV ::AFFIMED REPORTS 2018 FINANCIAL RESULTS AND OPERATIONAL PROGRESS.AFFIMED NV - AFM24: IND SUBMISSION PLANNED FOR MID-2019; PLANS TO INITIATE FIRST-IN-HUMAN STUDY IN SECOND HALF OF 2019.AFFIMED NV - CLINICAL DATA UPDATES FROM MONOTHERAPY STUDY AND COMBINATION STUDY WITH KEYTRUDA (PEMBROLIZUMAB) EXPECTED IN 2019.
Full Article
Oct 8 (Reuters) - Affimed NV ::AFFIMED PLACES AFM11 (CD19/CD3-TARGETING T CELL ENGAGER) PHASE 1 PROGRAM ON CLINICAL HOLD.AFFIMED NV - ANNOUNCED THAT IT HAS PLACED AFM11 (CD19/CD3-TARGETING T CELL ENGAGER) ON CLINICAL HOLD.AFFIMED NV - CLINICAL HOLD WAS INITIATED AFTER OCCURRENCE OF SERIOUS ADVERSE EVENTS (SAES) IN THREE PATIENTS.AFFIMED NV - SERIOUS ADVERSE EVENTS (SAES) IN 3 PATIENTS, INCLUDED A DEATH IN ALL STUDY AND TWO LIFE-THREATENING EVENTS IN NHL STUDY.AFFIMED NV - SAES OCCURRED IN PATIENTS ENROLLED IN HIGHEST DOSE COHORTS OF EACH STUDY.AFFIMED NV - CLINICAL HOLD DOES NOT AFFECT ONGOING DEVELOPMENT OF CO'S NK CELL ENGAGER PROGRAMS, WHICH ARE BASED ON TARGETING NK CELL RECEPTOR CD16A.
Full Article
Sept 19 (Reuters) - Affimed NV ::SGR SAGITTARIUS HOLDING AG CUTS STAKE IN AFFIMED NV TO 11.9 PERCENT AS OF SEPTEMBER 10 FROM A STAKE OF 14.3 PERCENT AS OF MARCH 20 - SEC FILING.
Full Article
Aug 8 (Reuters) - Affimed NV ::AFFIMED REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2018 AND OPERATIONAL PROGRESS.Q2 LOSS PER SHARE EUR 0.13.Q2 REVENUE EUR 200,000 VERSUS EUR 500,000.Q2 REVENUE VIEW EUR 407,000 -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW EUR -0.15 -- THOMSON REUTERS I/B/E/S.CASH AND CASH EQUIVALENTS TOTALED EUR 47.4 MILLION AS OF JUNE 30, 2018 COMPARED TO EUR 39.8 MILLION AS OF DECEMBER 31, 2017.
Full Article
March 20 (Reuters) - Affimed Nv ::AFFIMED REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND YEAR END 2017.Q4 LOSS PER SHARE EUR 0.14.Q4 EARNINGS PER SHARE VIEW EUR -0.17 -- THOMSON REUTERS I/B/E/S.Q4 REVENUE EUR 600,000 VERSUS EUR 1.4 MILLION.Q4 REVENUE VIEW EUR 1.8 MILLION -- THOMSON REUTERS I/B/E/S.OPERATIONS, INCLUDING CLINICAL DEVELOPMENT AND EARLY DEVELOPMENT ACTIVITIES, ARE EXPECTED TO BE FUNDED AT LEAST UNTIL Q4 OF 2019.
Full Article
Feb 13 (Reuters) - Affimed Nv ::AFFIMED ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 11.5 MILLION COMMON SHARES PRICED AT $2.00PER SHARE.
Full Article
Feb 12 (Reuters) - Affimed Nv ::AFFIMED ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.
Full Article
Feb 1 (Reuters) - Affimed Nv ::AFFIMED REPORTS NEW DATA FOR AFM13 FROM TWO SEPARATE CLINICAL TRIALS IN HODGKIN AND CD30-POSITIVE LYMPHOMAS.AFFIMED NV - DATA DEMONSTRATE THAT AFM13 WAS WELL-TOLERATED.AFFIMED NV - DATA DEMONSTRATE AFM13 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) DOUBLED COMPLETE RESPONSE RATE IN HODGKIN LYMPHOMA PATIENTS.AFFIMED NV - EARLY DATA SUGGEST NEW OPPORTUNITY FOR AFM13 IN CD30-POSITIVE LYMPHOMA.AFFIMED NV - AFM13 IS CLINICALLY ACTIVE AND WELL-TOLERATED AS MONO- AND COMBINATION THERAPY.AFFIMED NV - AFM13 IN COMBINATION WITH KEYTRUDA WAS WELL-TOLERATED WITH MOST OF ADVERSE EVENTS OBSERVED MILD TO MODERATE IN NATURE.
Full Article
Nov 7 (Reuters) - Affimed Nv :Affimed reports financial results for third quarter 2017.Q3 loss per share EUR 0.18.Q3 earnings per share view EUR -0.17 -- Thomson Reuters I/B/E/S.Q3 revenue eur 500,000 versus EUR 900,000.Q3 revenue view EUR 933,000 -- Thomson Reuters I/B/E/S.
Full Article
Oct 30 (Reuters) - Affimed Nv :Affimed announces third quarter 2017 financial results and corporate update conference call.
Full Article
Earnings vs. 
Estimates